179 results
8-K
EX-99.1
DYAI
Dyadic International, Inc.
13 Aug 24
Dyadic Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress
4:17pm
to eight collaborations for the same period a year ago.
Cost of Revenue: Cost of research and development revenue for the three months ended June 30 … , 2024, decreased to approximately $302,000 compared to $793,000 for the same period a year ago. The decrease in cost of research and development
8-K
EX-10.1
DYAI
Dyadic International, Inc.
2 Jul 24
Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership
9:29am
, compensation information, pricing information, specifications, devices, research and development data, manufacturing and processing data, clinical … $500,000 of the License Fee associated with Section 5.1 iii into tech transfer, further research and development, scale up, regulatory support
8-K
EX-10.1
DYAI
Dyadic International, Inc.
2 Jul 24
Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership
9:28am
, compensation information, pricing information, specifications, devices, research and development data, manufacturing and processing data, clinical … $500,000 of the License Fee associated with Section 5.1 iii into tech transfer, further research and development, scale up, regulatory support
8-K
EX-99.1
DYAI
Dyadic International, Inc.
14 May 24
Dyadic Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
4:47pm
, fully funded research and development costs, and specified product milestones and royalties upon commercialization.
On February 21, 2024, the Company … as of December 31, 2023.
Revenue: Research and development revenue and license revenue for the three months ended March 31, 2024, decreased to approximately
8-K
EX-99.1
6mjxo2 igr79bpkk
28 Mar 24
Dyadic Reports 2023 Full Year Results and Recent Company Progress
4:07pm
8-K
EX-99.1
sydxvc11
8 Nov 23
Dyadic Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
4:09pm
8-K
EX-99.1
iqnq0l7v lyz81jsdgsc
9 Aug 23
Dyadic Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
4:08pm
8-K
EX-99.1
f8vi1
10 May 23
Dyadic Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
4:35pm
8-K
EX-10.1
b0wy68g lr1gnsf0q
12 Apr 23
Dyadic Announces Expanded Licensing Agreement to Develop and Commercialize Vaccines and Biologics for African Continent
8:30am